Brief: Oragenics Project To Develop Variant-Agnostic Protein Antigen For Use
05/06/2023 22:38
June 5 (Reuters) - Oragenics Inc OGEN.A :
* ORAGENICS PROJECT TO DEVELOP A VARIANT-AGNOSTIC PROTEIN
ANTIGEN
FOR USE IN ITS COVID-19 INTRANASAL VACCINE RECEIVES FUNDING FROM
CQDM
* ORAGENICS INC- IN MARCH 2023, ENTERED EXCLUSIVE GLOBAL
LICENSE
AGREEMENT WITH INSPIREVAX FOR ITS NOVEL INTRANASAL MUCOSAL
ADJUVANT, BDX301
* ORAGENICS INC- PROJECT IS A COLLABORATION WITH NATIONAL
RESEARCH
COUNCIL OF CANADA (NRC) AND INSPIREVAX
Source text for Eikon: ID:nBw57wVT2a
Further company coverage: OGEN.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oragenics
See all newsBrief: Oragenics Reports Continued Clinical Progress, Provides Regulatory And NYSE American Listing Update
Brief: Oragenics Signs Letter Of Intent To License Cardiodialysis™ Technology From Sigyn Therapeutics To Target Tbi-Induced Systemic Inflammation
Brief: Oragenics Inc - Signs Letter Of Intent To License Cardiodialysis From Sigyn Therapeutics - SEC Filing
Brief: Oragenics Activates Second Site In Phase Iia Clinical Trial Of Onp-002 For Concussion And Mild Traumatic Brain Injury.
Brief: Oragenics Enters Settlement Agreement With Ladenburg Thalmann - Sec Filing